SCHEDULE 13D/A: OrbiMed Advisors Exits Significant Stake in Disc Medicine, Inc. with Latest Share Sales

OrbiMed Advisors and its affiliated entities have filed an Amendment No. 5 to their Schedule 13D, indicating they have ceased to be beneficial owners of more than 5% of Disc Medicine, Inc.'s common stock following recent share dispositions.

Summary

• OrbiMed Advisors LLC and its affiliates (OrbiMed Capital GP VI LLC, OrbiMed Capital GP VIII LLC, and OrbiMed Genesis GP LLC) have filed an Amendment No. 5 to their Schedule 13D regarding their investment in Disc Medicine, Inc.
• This filing serves as an "exit filing," reporting that the Reporting Persons no longer beneficially own more than 5% of Disc Medicine, Inc.'s common stock as of March 11, 2025.
• The total aggregate amount beneficially owned by OrbiMed Advisors LLC is 1,556,369 shares, representing 4.5% of the class.
• This percentage is based on 34,569,042 shares of Disc Medicine, Inc. common stock outstanding, as reported in the Issuer's Annual Report on Form 10-K filed on February 27, 2025.
• Significant share sales occurred on March 10, 2025, and March 11, 2025, at weighted average prices ranging from $54.00 to $55.01 per share.
• Specifically, on March 10, 2025, OPI VI sold 68,766 shares at $54.29 and 136 shares at $55.01; OPI VIII sold 106,384 shares at $54.29 and 211 shares at $55.01; and Genesis sold 26,596 shares at $54.29 and 53 shares at $55.01.
• On March 11, 2025, OPI VI sold 9,222 shares at $54.01; OPI VIII sold 14,267 shares at $54.00; and Genesis sold 3,567 shares at $54.01.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative because a significant institutional investor has reduced its stake below the 5% threshold, which can be interpreted by the market as a lack of long-term conviction or a belief that the stock has reached its near-term potential, despite the sales occurring at favorable prices for the seller.

Positives

• The sales occurred at relatively high prices (around $54-$55 per share), indicating a potentially favorable exit point for OrbiMed.
• The exit of a large institutional investor could reduce overhang on the stock, potentially allowing new investors to enter.

Negatives

• The reduction of a significant stake by a major institutional investor like OrbiMed could be perceived negatively by the market, potentially signaling a lack of long-term conviction or a belief that the stock has reached its near-term potential.
• The exit of a board member affiliated with OrbiMed (Mona Ashiya, though not explicitly stated she is leaving the board, her affiliation with the exiting investor group is notable) could reduce institutional oversight or strategic input.

Risks

• The market might interpret OrbiMed's exit as a negative signal regarding Disc Medicine's future prospects or valuation, potentially leading to downward pressure on the stock price.
• Reduced institutional ownership could lead to lower trading liquidity or increased volatility.

Future Outlook

The Reporting Persons state their intent to review their investment in Disc Medicine, Inc. based on various factors, including the Issuer's business, financial condition, and market conditions. They may acquire or dispose of shares in the future depending on market and other factors, but have not formulated specific plans for extraordinary corporate transactions or changes to the Issuer's structure.

Industry Context

This filing reflects a common practice among institutional investors to adjust their portfolio holdings based on investment theses, market conditions, or internal portfolio rebalancing. OrbiMed is a prominent healthcare-focused investment firm, and its exit from a significant stake in a biotechnology company like Disc Medicine could be seen as a strategic move within the dynamic biotech investment landscape.

Comparison to Industry Standards

• This document does not provide specific financial results or operational data for Disc Medicine, Inc. that would allow for a direct comparison to industry standards or specific comparable companies/projects. It primarily details a change in beneficial ownership by an institutional investor.

Corporate Governance

Related Party Transactions

• Mona Ashiya, a board member of Disc Medicine and an employee of OrbiMed Advisors, has an agreement to transfer any equity-based compensation from Disc Medicine to OrbiMed entities.

Stakeholder Impact

• Shareholders: Existing shareholders might view the reduction of OrbiMed's stake negatively, potentially leading to a decrease in share price due to perceived loss of institutional confidence. New investors might see this as an opportunity if they believe the stock is undervalued post-exit.
• Management: Disc Medicine's management might need to address market concerns regarding the institutional investor's exit and potentially seek new long-term investors.

Next Steps

• The Reporting Persons will continue to review their investment in Disc Medicine, Inc.
• They may acquire or dispose of additional shares or other securities of the Issuer in the open market or privately negotiated transactions in the future.
• The Reporting Persons undertake to provide full information regarding the number of shares sold at each separate price upon request by the SEC staff or the Issuer.

Key Dates

Recommendation

Keywords

Disc Medicine Inc., OrbiMed Advisors, Schedule 13D/A, Beneficial Ownership, Share Sales, Institutional Investor, SEC Filing, Biotechnology, Healthcare Investment, Exit Filing